Safety and Efficacy
Discoveries from four clinical studies document the safety and efficacy of ReadiSorb® Liposomal Glutathione (RLG) in restoring glutathione levels among both adults (1-3) and children (4). These studies were conducted in individuals dealing with conditions characterized by low glutathione (GSH) levels, including HIV (1, 2), Type 2 Diabetes Mellitus (T2DM) (3), and autism (4).
Advantages compared to NAC and Plain GSH
Before the ReadiSorb® Liposomal Glutathione clinical studies, cell studies highlighted a remarkable distinction: ReadiSorb® Liposomal Glutathione will restore glutathione levels and macrophage immune defense 1,000 times more efficiently than N-acetyl cysteine (NAC) (5, 6). This means that achieving the same outcome required NAC to be administered at a dosage 1,000 times larger than ReadiSorb® Glutathione (5, 6).
RLG is 100 times more potent than plain GSH in restoring GSH to cells and in cell defense against pesticide toxicity (7).
The advantage of liposomal glutathione is further amplified by the observation that liposomes are known to accumulate at sites of inflammation and are taken up by macrophages (8) (van Alem 2021).
Macrophages constitute a vital component of the immune defense system, and the crucial role glutathione plays in their function is described in references (1-3).
References
- Ly J, Lagman M, Saing T, Singh MK, Tudela EV, Morris D, et al. Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals. J Interferon Cytokine Res. 2015;35(11):875-87. PMCID: 4642835. http://www.ncbi.nlm.nih.gov/pubmed/26133750
- Valdivia A, Ly J, Gonzalez L, Hussain P, Aing T, Islamoglu H, et al. Restoring cytokine balance in HIV Positive Individuals with Low CD4 T Cell Counts. AIDS Res Hum Retroviruses. 2017. http://www.ncbi.nlm.nih.gov/pubmed/28398068
- To K, Cao R, Yegiazaryan A, Owens J, Nguyen T, Sasaninia K, et al. Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes. Front Cell Infect Microbiol. 2021;11:657775. PMCID: PMC8211104. https://www.frontiersin.org/articles/10.3389/fcimb.2021.657775/full
- Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR. A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit. 2011;17(12):CR677-82. http://www.ncbi.nlm.nih.gov/pubmed/22129897
- Morris D, Guerra C, Khurasany M, Guilford F, Saviola B, Huang Y, et al. Glutathione supplementation improves macrophage functions in HIV. J Interferon Cytokine Res. 2013;33(5):270-9. http://www.ncbi.nlm.nih.gov/pubmed/23409922
- Lagman M, Ly J, Saing T, Kaur Singh M, Vera Tudela E, Morris D, et al. Investigating the Causes for Decreased Levels of Glutathione in Individuals with Type II Diabetes. PLoS One. 2015;10(3):e0118436. http://www.ncbi.nlm.nih.gov/pubmed/25790445
- Zeevalk GD, Bernard LP, Guilford FT. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. Neurochem Res. 2010;35(10):1575-87. https://pubmed.ncbi.nlm.nih.gov/20535554/
- van Alem CMA, Metselaar JM, van Kooten C, Rotmans JI. Recent Advances in Liposomal-Based Anti-Inflammatory Therapy. Pharmaceutics. 2021;13(7). PMCID: PMC8309101. https://www.ncbi.nlm.nih.gov/pubmed/34371695